To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.

119-hr1051 — To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.. Sponsored by Rep. Budzinski, Nikki [D-IL-13]. Introduced 2025-02-06. House bill. 119th Congress. Latest action: Referred to the House Committee on Energy and Commerce.

No roll-call vote data available for this bill.